Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$321.38M+65.01%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alton E. Shader
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 3,000
- Beta
- 1.85
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.91
Financials
Revenue
$321.38M+65.0%Net Income
$53.64M+745.8%EBITDA
$145.85M+62.7%Free Cash Flow
$42.05M+58.2%EPS (diluted)
$0.19+596.0%Shares Outstanding (diluted)
288.15M+24.0%Operating Expenses
$68.16MCash & Debt
$356.73MReturn of Capital
$0.00Revenue by Segment (annual)
$1.16BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.16B | $77.95M | $0.27 |
| 2024 | $1.10B | $44.40M | $0.16 |
| 2023 | $1.05B | $51.38M | $0.18 |
| 2022 | $1.00B | $-233.57M | $-0.83 |
| 2021 | $931.48M | $116.88M | $0.41 |
| 2020 | $818.16M | $-38.62M | $-0.14 |
| 2019 | $778.33M | $-20.85M | $-0.07 |
| 2018 | $746.15M | $-5.87M | $-0.02 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.40
- Implied price
- $7.26
- Return from $18.10
- -16.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.61 — -80.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -30.3% | -27.1% | -24.4% | -22.0% | -19.9% |
| 3.0% | -26.7% | -23.4% | -20.6% | -18.1% | -15.8% |
| 8.0% | -23.2% | -19.7% | -16.7% | -14.1% | -11.8% |
| 13.0% | -19.6% | -16.0% | -12.8% | -10.1% | -7.7% |
| 18.0% | -16.1% | -12.2% | -9.0% | -6.1% | -3.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
153-9.80%Social Signal Score
Mentions (5)
- News (RSS)seekingalpha·36d ago·Neutral
Sotera Health: Pricing Power And Recurring Revenues Are Growth Drivers
View source ↗ - Newsseekingalpha.com·36d ago·Neutral
…g Revenues Are Growth Drivers Sotera Health Company is rated BUY, leveraging a vertically integrated model and strong MOAT in global medical equipment sterilization. SHC benefits from high customer switching costs, multi-year contracts with major healthcare firms, and robust pricing power in mission critical services. Q2 2026 results exceeded expectations, prompting raised full-year guidance; SHC trades at a discount to peers on forward EV/EBITDA despite superior margins.
View source ↗ - News (RSS)yahoo·39d ago·Neutral
Here’s Why Sotera Health Company (SHC) Surges 25% in Q2
View source ↗ - News (RSS)seekingalpha·45d ago·Positive
Sotera Health Company (SHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·45d ago·Positive
Sotera Health Company (SHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Sotera Health Company (SHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗
Earnings
Tue, Nov 3(in 9 days)
Consensus estimate $0.27 per share
Typical surprise +8.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.26 vs $0.24beat
- Tue, May 5$0.18 vs $0.17beat
- Tue, Feb 24$0.26 vs $0.24beat
- Tue, Nov 4$0.26 vs $0.22beat
- Fri, Aug 8$0.20 vs $0.17beat
- Thu, May 1$0.14 vs $0.12beat
Estimates and results for SHC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SHC officers and directors.
- Bought
- —
- Sold
- $2.3bn
0 trades
19 trades
- Petras Michael B. Jr.sold
- Petras Michael B. Jr.sold
- Rutz Michael Psold
- Warburg Pincus & Co.sold
- Gtcr Investment Xi Llcsold
- Warburg Pincus & Co.sold
- Gtcr Investment Xi Llcsold
- Petras Michael B. Jr.sold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SHC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.